No Data
No Data
Stereotaxis Positioned for 2025 Growth: Buy Rating Backed by Strong Pipeline, Regulatory Approvals, and Solid Financials
Express News | Stereotaxis' Genesis Robotic System Debuts in Finland, Treats First Patients
Why Stereotaxis (STXS) Is Among the Cheap Robotics Stocks to Invest In Now?
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis and MicroPort EP Secure NMPA Approval for Magbot Ablation Catheter in China
Stereotaxis' GenesisX Robotic System to Be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems